Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: A phase II trial of the Gynecologic Oncology Group

Journal of Clinical Oncology

Volumn 21, Issue 2, 2003, Pages 283-290

  Bookman, Michael A ^a   Darcy, Kathleen M ^a   Clarke Pearson, Daniel ^a   Boothby, Richard A ^a   Horowitz, Ira R ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ARTICLE; BLOOD ANALYSIS; CANCER GROWTH; CANCER PATIENT; CANCER SCREENING; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; FEASIBILITY STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PERITONEUM CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENT CANCER; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ADENOCARCINOMA; ADULT; AGED; CLINICAL TRIAL; CYSTADENOCARCINOMA; DISEASE FREE SURVIVAL; ENDOMETRIOID CARCINOMA; ENZYME IMMUNOASSAY; EVALUATION; FEMALE; METABOLISM; MIDDLE AGED; OVARY TUMOR; PATHOLOGY; PERITONEUM TUMOR; PHASE 2 CLINICAL TRIAL; TUMOR RECURRENCE;

ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, ENDOMETRIOID; CYSTADENOCARCINOMA, SEROUS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; RECEPTOR, ERBB-2;

EID: 0037440042     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.10.104     Document Type: Article

References (32)

1. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987
2. Slamon DJ, Godcphin W, Jones LA, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712, 1989
3. Bargmann CI, Weinberg RA: Oncogenic activation of the neu-encoded receptor by point mutation and deletion. EMBO J 7:2043-2052, 1988
4. Bargmann CI, Hung MC, Weinberg RA: Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell 45:649-657, 1986
5. Muller WJ, Sinn E, Pattengale PK, et al: Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 54:105-115, 1998
6. Guy CT, Webster MA, Schaller M, et al: Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci U S A 89:10578-10582, 1992
7. Chazin VR, Kaledo M, Miller AD, et al: Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor. Oncogene 7:1859-1866, 1992
8. Di Fiore PP, Pierce JH, Kraus MH, et al: erbB-2 is a potent oncogene when overexpressed in NIH-3T3 cells. Science 237:178-182, 1987
9. Hudziak RM, Schlessinger J, Ullrich A: Increased expression of the putative growth factor receptor p185 HER2 causes transformation and tumorigenesis of NIH-3T3 cells. Proc Natl Acad Sci U S A 84:7159-7163, 1987
10. Drebin JA, Link VC, Stern DF, et al: Down modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell 41:695-706, 1985
11. Drebin JA, Link VC, Greene ML: Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo. Oncogene 2:387-394, 1988
12. Fendly BM, Winget M, Hudziak RM, et al: Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res 50:1550-1558, 1990
13. Lewis GD, Figari I, Fendly B, et al: Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol Immunother 37:255-263, 1993
14. Shepard HM, Lewis GD, Sarup JC, et al: Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic. J Clin Immunol 11:117-127, 1991
15. Carter P, Presta L, Gorman CM, et al: Humanization of an anti-p185HER2 antibody for human cancer treatment. Proc Natl Acad Sci U S A 89:4285-4289, 1992
16. Baselga J, Tripathy D, Mendelsohn J, et al: Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14:737-744, 1996
17. Cobleigh MA, Vogel CL, Tripathy D, et al: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639-2648, 1999
18. Rubin SC, Finstad CL, Federici MG, et al: Prevalence and significance of Her-2/neu expression in early epithelial ovarian cancer. Cancer 73:1456-1459, 1994
19. Berchuck A, Kamel A, Whitaker R, et al: Overexpression of HER-2 neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 50:4087-4091, 1990
20. Rubin SC, Finstad CL, Wong GY, et al: Prognostic significance of HER-2/neu expression in advanced epithelial ovarian cancer: A multivariate analysis. Am J Obstet Gynecol 168:162-169, 1993
21. Taylor SL, Platt-Higgins A, Rudland PS, et al: Cytoplasmic staining of c-erbB-2 is not associated with the presence of detectable c-erB-2 mRNA in breast cancer specimens. Int J Cancer 76:459-463, 1998
22. Têtu B, Brisson J: Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer: The influence of the pattern of immunostaining and adjuvant therapy. Cancer 73:2359-2365, 1994
23. Press MF, Hung G, Godolphin W, et al: Sensitivity of HER2/neu antibodies in archival tissue samples: Potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 54:2771-2777, 1994
24. Roche PC, Ingle JN: Increased HER2 with U.S. Food and Drug Administration-approved antibody. J Clin Oncol 17:434, 1999
25. Scott GK, Robles R, Park JW, et al: A truncated intracellular HER2/neu receptor produced by alternative RNA processing affects growth of human carcinoma cells. Mol Cell Biol 13:2247-2253, 1993
26. Pietras RJ, Fendly BM, Chazin VR, et al: Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 9:182-188, 1994
27. Arteaga CL, Winnier AR, Poirier MC, et al: P185C4rb B-2 signaling enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: Association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair. Cancer Res 54:3758-3765, 1994
28. Hancock MC, Langton BC, Chan T, et al: A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res 51:4575-4580, 1991
29. Pegram MD, Pietras RJ, Slamon DJ: Monoclonal antibody to HER-2/neu gene product potentiates cytotoxicity of carboplatin and doxorubicin in human breast tumor cells. Proc Am Assoc Cancer Res 33:442, 1992 (abstr)
30. Baselga J, Norton L, Coplan K, et al: Antitumor activity of paclitaxel in combination with anti-growth factor receptor monoclonal antibodies in breast cancer xenografts. Proc Am Assoc Cancer Res 35:380, 1994 (abstr)
31. Pegram MD, Lipton A, Hayes DF, et al: Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/ neu monoclonal antibody plus cisplatin in patients with HER2/neu- overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16:2659-2671, 1998
32. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001